Pacific Biosciences Of California (PACB) Capital Expenditures Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Pacific Biosciences Of California | 481.66 Mn | 205.70 Mn | 12.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 49.98% |
| Dec 31, 2025 | 66.64% |
| Sep 30, 2025 | -16.66% |
| Jun 30, 2025 | 11.51% |
| Mar 31, 2025 | 64.02% |
| Dec 31, 2024 | 62.89% |
| Sep 30, 2024 | -24.15% |
| Jun 30, 2024 | 19.26% |
| Mar 31, 2024 | 25.36% |
| Dec 31, 2023 | 103.50% |
| Sep 30, 2023 | 53.94% |
| Jun 30, 2023 | 10.83% |
| Mar 31, 2023 | 61.00% |
| Dec 31, 2022 | 35.85% |
| Sep 30, 2022 | 5.16% |
| Jun 30, 2022 | 3.11% |
| Mar 31, 2022 | 6.40% |
| Dec 31, 2021 | 1.40% |
| Jun 30, 2021 | -10.93% |
| Mar 31, 2021 | -2.58% |
| Dec 31, 2020 | -40.23% |
| Sep 30, 2020 | 3.15% |
| Jun 30, 2020 | -19.69% |
| Mar 31, 2020 | -30.41% |
| Dec 31, 2019 | -21.63% |
| Sep 30, 2019 | 34.26% |
| Jun 30, 2019 | 5.68% |
| Mar 31, 2019 | 21.31% |
| Dec 31, 2018 | -10.68% |
| Sep 30, 2018 | -16.03% |
| Jun 30, 2018 | 37.09% |
| Mar 31, 2018 | 2.98% |
| Dec 31, 2017 | 19.23% |
| Sep 30, 2017 | 46.54% |
| Jun 30, 2017 | 46.73% |
| Mar 31, 2017 | 57.65% |
| Dec 31, 2016 | 13.01% |
| Sep 30, 2016 | 0.38% |
| Jun 30, 2016 | -7.32% |
| Mar 31, 2016 | -21.11% |
| Dec 31, 2015 | -6.50% |
| Sep 30, 2015 | -15.06% |